Haloperidol

also known as Haldol · haloperidole · 18F-haloperidol · [19F]-HALOPERIDOL · Dolpin · Dozic · Fortunan · HAL · +15 more

Other / unclassified targets DRD2, HTR2A via inhibition

Developed for: delirium · schizophrenia · psychotic disorder · cannabinoid hyperemesis syndrome · Alzheimer disease · cannabis dependence · chronic pain syndrome · gastroparesis
+13 more
· glioblastoma · Huntington disease · hyperlipidemia · mental disorder · migraine disorder · schizoaffective disorder · subacute delirium · bipolar disorder · bipolar I disorder · cyclic vomiting syndrome · female reproductive system disorder · headache disorder · mood disorder
Investigated by: National Cancer Institute (NCI) · German Research Network On Schizophrenia · Heinrich-Heine University, Duesseldorf · Janssen-Cilag Ltd. · M.D. Anderson Cancer Center · Mainz University
+88 more
· Martin-Luther-University Halle-Wittenberg · National Institute on Aging (NIA) · RWTH Aachen University · University Hospital Tuebingen · University of Cologne · University of Duisburg-Essen · University of Göttingen · University of Jena · University of Mannheim · University of Wuerzburg · American Cancer Society, Inc. · Canadian Institutes of Health Research (CIHR) · Centre for Addiction and Mental Health · Eli Lilly and Company · German Federal Ministry of Education and Research · Humboldt-Universität zu Berlin · Indiana University · Ludwig-Maximilians - University of Munich · University of Bonn · Virginia Commonwealth University · Western Michigan University School of Medicine · Ain Shams University · Alberta Health services · Beersheva Mental Health Center · Beijing HuiLongGuan Hospital · Bristol-Myers Squibb · Bronson Methodist Hospital · Canadian Psychiatric Research Foundation · Cancer Prevention Research Institute of Texas · Case Western Reserve University · Catholic Health East · Centre for Research in Intensive Care (CRIC) · Christian Medical College, Vellore, India · Copenhagen Trial Unit, Center for Clinical Intervention Research · Demensforbundet, Norway · Denver Health Medical Center · Department of Psychiatry University FU Berlin · Department of Psychiatry University of Bonn · Dr. Marco L.A. Sivilotti · Dutch Diabetes Research Foundation · Fundacion Clinic per a la Recerca Biomédica · Fundación Pública Andaluza Progreso y Salud · HCA Hospice Care · Hannover Medical School · Hennepin Healthcare Research Institute · Hospital Clinic of Barcelona · Innlandet Hospital Trust · Instituto de Salud Carlos III · Juntendo University · King's College London · Leiden University Medical Center · Mario Negri Institute for Pharmacological Research · Medical Research Council · Michelle Weckmann · National Heart, Lung, and Blood Institute (NHLBI) · National Institute of Medical Sciences and Nutrition Salvador Zubiran · National Institute of Nursing Research (NINR) · National Institute on Drug Abuse (NIDA) · National Institutes of Health (NIH) · Northeastern University · OhioHealth · Quebec Firefighters Foundation for Burns · Radboud University Medical Center · Rully Riyandika · Sant Pau Research Institute · Scandinavian Critical Care Trials Group · Second Affiliated Hospital, School of Medicine, Zhejiang University · Southern Medical University, China · Technical University of Munich · Tehran University of Medical Sciences · The Danish Centre of Applied Social Science (VIVE) · The Physicians' Services Incorporated Foundation · The University of Texas Health Science Center, Houston · UMC Utrecht · all 94 on the full record

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	US (FDA)	HALDOL	—	1967-04-12	fda.gov ↗

Trials 58

today

US approved 1967

19661967196819691970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT07726069	Nov 2026 → Jan 2028 expected	cannabinoid hyperemesis syndrome	University of Illinois at Chicago	Not yet recruiting	No outcome recorded
Phase 14 trials
Phase 1	NCT04071639	Mar 2020 → Dec 2024	Huntington disease	Second Affiliated Hospital, School of Medicine, Zhejiang University	Unknown	No outcome recorded
Phase 1	NCT03754062	Jun 2017 → Sep 2019	—	King's College London	Completed	No outcome recorded
Phase 1	NCT01924468	Aug 2013 → Sep 2018	nicotine dependence	National Institute on Drug Abuse (NIDA)	Completed	No outcome recorded
Phase 1	NCT01259973	Feb → Nov 2011	—	Hospital Clinic of Barcelona	Unknown	No outcome recorded
Phase 23 trials
Phase 2	NCT06218524	Dec 2024 → Dec 2027 expected	glioblastoma	Southern Medical University, China	Not yet recruiting	No outcome recorded
Phase 2	NCT04750395	Sep 2021 → May 2024	delirium	HCA Hospice Care	Unknown	No outcome recorded
Phase 2	NCT00429676	Dec 2005 → Sep 2007	delirium	University of Colorado, Denver	Completed	No outcome recorded
Phase 2/34 trials · 1 met primary · 1 missed
Phase 2/3	NCT06168773	Nov 2022 → Oct 2023	delirium	Ain Shams University	Completed	No outcome recorded
Phase 2/3	NCT05431595	Jul 2022 → Feb 2027 expected	delirium, epilepsy	M.D. Anderson Cancer Center	Recruiting	No outcome recorded
Phase 2/3	NCT03743649	Jul 2019 → Dec 2028 expected	delirium, high grade malignant neoplasm, metastatic malignant neoplasm	M.D. Anderson Cancer Center	Active not recruiting	Met primary
Phase 2/3	NCT03021486	Jun 2017 → Jun 2021 overdue	delirium, metastatic malignant neoplasm	M.D. Anderson Cancer Center	Active not recruiting	Missed primary
Phase 312 trials · 2 missed
Phase 3	NCT02345902	Jan 2016 → Mar 2018	delirium	National Institute of Medical Sciences and Nutrition Salvador Zubiran	Unknown	No outcome recorded
Phase 3	NCT02374567	Jan 2015 → Jun 2017	anxiety disorder, dementia, depressive disorder, schizophrenia +1	Hannover Medical School	Terminated	No outcome recorded
Phase 3	NCT01811459	Feb 2013 → Sep 2016	delirium	University of Montreal Hospital Centre (CHUM)	Completed	No outcome recorded
Phase 3	NCT01765829	Nov 2012 → Nov 2015	psychotic disorder	Fundación Pública Andaluza Progreso y Salud	Unknown	No outcome recorded
Phase 3	NCT01211522	Dec 2011 → Aug 2017	delirium, mental disorder	Vanderbilt University Medical Center	Completed	Missed primary
Phase 3	NCT00599287	Feb → May 2008	delirium	UMC Utrecht	Terminated	No outcome recorded
Phase 3	NCT00300391	Mar 2006 → Oct 2011	delirium	University of Pittsburgh	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT00455234	Sep 2005 → Jul 2006	psychotic disorder	Christian Medical College, Vellore, India	Completed	No outcome recorded
Phase 3	NCT00124930	May 2005 → Jun 2008	cancer or benign tumor	Alberta Health services	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT00485901	Jul 2004 → Jan 2005	schizophrenia	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00000179	—	Alzheimer disease	National Institute on Aging (NIA)	Completed	Missed primary
Phase 3	NCT00189995	—	schizophrenia	Beersheva Mental Health Center	Withdrawn	No outcome recorded

Phase 423 trials · 3 met primary · 4 missed
Phase 4	NCT07109245	Dec 2025 → Aug 2028 expected	acute insulin response	Centre for Addiction and Mental Health	Recruiting	No outcome recorded
Phase 4	NCT06395428	Jul 2024 → Apr 2025 overdue	chronic pain syndrome	Western Michigan University School of Medicine	Recruiting	No outcome recorded
Phase 4	NCT04764344	Apr 2021 → May 2023	—	Western Michigan University School of Medicine	Completed	No outcome recorded
Phase 4	NCT04176055	Oct 2020 → Jun 2021	cannabinoid hyperemesis syndrome	University of Calgary	Completed	No outcome recorded
Phase 4	NCT03392376	Jun 2018 → Jul 2022	delirium	Zealand University Hospital	Unknown	Missed primary
Phase 4	NCT03199950	Jun 2017 → Nov 2018	delirium	Zuyderland Medical Center	Unknown	No outcome recorded
Phase 4	NCT03056482	May 2017 → Jun 2019	cannabis dependence	Dr. Marco L.A. Sivilotti	Completed	Met primary
Phase 4	NCT02909465	Jul 2016 → Apr 2017	—	Tehran University of Medical Sciences	Completed	Met primary
Phase 4	NCT02307396	Feb 2015 → Jun 2016	schizoaffective disorder, schizophrenia	Technical University of Munich	Completed	No outcome recorded
Phase 4	NCT02103881	Apr → Jun 2014	—	Hennepin Healthcare Research Institute	Withdrawn	No outcome recorded
Phase 4	NCT02972502	Feb 2014 → Apr 2017	migraine disorder	OhioHealth	Terminated	No outcome recorded
Phase 4	NCT02213900	Sep 2013 → Dec 2015	anxiety, delirium, depressive disorder, post-traumatic stress disorder	Indiana University	Completed	Missed primary
Phase 4	NCT01785290	Jun 2013 → Dec 2016	delirium	Radboud University Medical Center	Completed	Missed primary
Phase 4	NCT02057549	Nov 2012 → Nov 2016	gastroparesis	The University of Texas Health Science Center, Houston	Terminated	Met primary
Phase 4	NCT03489551	Nov 2011 → Jul 2013	delirium, disease related to hematopoietic stem cell transplant	Michelle Weckmann	Completed	No outcome recorded
Phase 4	NCT01174290	Sep 2010 → Aug 2013	subacute delirium	Northeastern University	Completed	No outcome recorded
Phase 4	NCT01016145	Apr 2009 → Jun 2010	psychotic disorder	University of Sao Paulo	Unknown	No outcome recorded
Phase 4	NCT01052389	Jul 2007 → Jun 2012	schizophrenia	Mario Negri Institute for Pharmacological Research	Completed	No outcome recorded
Phase 4	NCT00433121	Sep 2006 → Aug 2007	dementia	Innlandet Hospital Trust	Completed	No outcome recorded
Phase 4	NCT00191555	Aug 2003 → May 2006	schizophrenia	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00159133	Nov 2001 → Jun 2006	schizophrenia	Heinrich-Heine University, Duesseldorf	Completed	No outcome recorded
Phase 4	NCT00157378	Nov 2000 → Dec 2004	schizophrenia	Ludwig-Maximilians - University of Munich	Unknown	No outcome recorded
Phase 4	NCT00159081	Nov 2000 → Jun 2005	schizophrenia	Heinrich-Heine University, Duesseldorf	Completed	Missed primary

Phase not applicable11 trials · 1 missed
—	NCT07087925	Jan → Apr 2025	—	Rully Riyandika	Completed	No outcome recorded
—	NCT02192723	Jun 2012 → Jun 2014	schizophrenia	Beijing HuiLongGuan Hospital	Completed	No outcome recorded
—	NCT01556932	Mar 2012 → May 2013	—	Virginia Commonwealth University	Completed	No outcome recorded
—	NCT01501123	Nov 2011 → Oct 2015	—	Catholic Health East	Completed	No outcome recorded
—	NCT03019887	Apr 2011 → Jan 2017	schizophrenia	Juntendo University	Completed	No outcome recorded
—	NCT01204255	Nov 2010 → Apr 2011	—	Virginia Commonwealth University	Completed	No outcome recorded
—	NCT01152697	Jun 2010 → Aug 2012	—	University Hospitals Cleveland Medical Center	Completed	No outcome recorded
—	NCT00842608	Feb 2009 → Jul 2015	delirium	Indiana University	Completed	Missed primary
—	NCT00493233	Nov 2006 → Dec 2008	schizophrenia	Centre for Addiction and Mental Health	Completed	No outcome recorded
—	NCT00625014	Mar → Jul 2005	hyperlipidemia	Leiden University Medical Center	Completed	No outcome recorded
—	NCT00018850	Jun 1998 → Jun 2003	schizophrenia	US Department of Veterans Affairs	Completed	No outcome recorded

Comparator or background therapy79 trials
Phase 0	NCT01684969 Comparator	Mar 2012 → May 2013	—	Eric E. Prommer	Withdrawn	No outcome recorded Stop: Enrollment
Phase 1	NCT01193621 Comparator	Jan 2008 → Jul 2010	—	Asan Medical Center	Completed	No outcome recorded
Phase 1/2	NCT02240173 Comparator	Jun → Dec 2017	schizophrenia	Federal Neuro-Psychiatric Hospital, Yaba	Unknown	No outcome recorded
Phase 2	NCT06428084 Comparator	Nov 2023 → Feb 2024	gallbladder disorder	Padjadjaran University	Completed	No outcome recorded
Phase 2	NCT04715230 Comparator	Jun 2021 → Oct 2022	methamphetamine-induced psychosis	InterveXion Therapeutics, LLC	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT04529226 Comparator	Nov 2020 → Jan 2025	intellectual disability, psychotic disorder	Andalusian Public Foundation for Health Research in Seville	Unknown	No outcome recorded
Phase 2	NCT03375671 Comparator	May 2018 → Mar 2020	—	David Barbic	Completed	No outcome recorded
Phase 2	NCT01323205 Background	May 2011 → Nov 2012	schizophrenia	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 2	NCT02203786 Comparator	Sep 2009 → Jun 2015	pathological gambling	Centre for Addiction and Mental Health	Completed	No outcome recorded
Phase 2	NCT00693472 Background	Aug 2007 → Dec 2008	drug-induced akathisia, movement disorder	Merck Sharp & Dohme LLC	Terminated	No outcome recorded
Phase 2	NCT00505804 Comparator	Jan 2005 → Nov 2008	delirium	Austin Health	Completed	No outcome recorded
Phase 2	NCT00096863 Comparator	Dec 2004 → Jul 2007	delirium	Vanderbilt University	Completed	No outcome recorded
Phase 2	NCT00044044 Comparator	Jul 2002 → May 2003	schizophrenia	Sumitomo Pharma America, Inc.	Completed	No outcome recorded
Phase 2/3	NCT00866645 Comparator	Feb 2009 → Jul 2010	—	Shanghai Mental Health Center	Completed	No outcome recorded
Phase 2/3	NCT00340379 Comparator	Apr 2003 → Aug 2005	mood disorder	Duke University	Completed	No outcome recorded
Phase 3	NCT07246187 Comparator	Nov 2025 → Oct 2026 expected	cannabinoid hyperemesis syndrome	Mercy Bon Secours Saint Vincent Medical Center	Recruiting	No outcome recorded
Phase 3	NCT06370442 Comparator	Jun 2024 → May 2025	mental disorder	State University of New York - Upstate Medical University	Unknown	No outcome recorded
Phase 3	NCT05690698 Comparator	Apr → Jul 2023	delirium	Alexandria University	Completed	No outcome recorded
Phase 3	NCT05803642 Comparator	Mar 2023 → May 2024	—	Qilu Pharmaceutical Co., Ltd.	Unknown	Met primary
Phase 3	NCT04833023 Comparator	May 2022 → Sep 2025	delirium	Tan Tock Seng Hospital	Completed	No outcome recorded
Phase 3	NCT05065567 Comparator	Aug 2021 → Nov 2023	cyclic vomiting syndrome	Corewell Health South	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT04081545 Background	Dec 2019 → Mar 2023	substance-related disorder	Christine Oryhan	Completed	No outcome recorded
Phase 3	NCT03628391 Comparator	Feb 2018 → Feb 2020	delirium, psychotic disorder	Erasmus Medical Center	Terminated	No outcome recorded
Phase 3	NCT02431702 Comparator	Jul 2015 → Nov 2019	schizophrenia	Janssen Scientific Affairs, LLC	Completed	Missed primary
Phase 3	NCT01862302 Comparator	Aug 2013 → Sep 2015	—	McMaster University	Completed	No outcome recorded
Phase 3	NCT01750541 Comparator	Dec 2012	—	Shahid Beheshti University of Medical Sciences	Completed	No outcome recorded
Phase 3	NCT01140529 Comparator	May 2010 → May 2012	delirium	Thorax-Kärlkliniken	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT01081769 Comparator	Feb 2010 → Feb 2013	schizophrenia	Janssen-Cilag International NV	Completed	Met primary
Phase 3	NCT00954603 Comparator	Jun 2009 → Apr 2011	delirium	Chiang Mai University	Terminated	Missed primary Stop: Enrollment
Phase 3	NCT00723606 Comparator	Sep 2008 → Jul 2009	schizophrenia	Viatris Inc.	Completed	No outcome recorded
Phase 3	NCT00797277 Comparator	Jul 2006 → Jun 2009	schizoaffective disorder, schizophrenia	National Taiwan University Hospital	Completed	Met primary
Phase 3	NCT00250237 Comparator	Nov 2005 → Nov 2008	delirium	Bronovo Hospital	Completed	No outcome recorded
Phase 3	NCT00156065 Comparator	Sep 2005 → Sep 2007	schizophrenia	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00156104 Comparator	Jul 2005 → Aug 2006	schizophrenia	Organon and Co	Completed	Met primary
Phase 3	NCT00129220 Comparator	Jul 2005 → Jan 2009	bipolar I disorder	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT00097266 Comparator	Dec 2004 → Jan 2007	bipolar disorder	Otsuka Pharmaceutical Development & Commercialization, Inc.	Completed	No outcome recorded
Phase 4	NCT05246631 Comparator	Jan → Mar 2020	—	Indonesia University	Completed	No outcome recorded
Phase 4	NCT03639558 Comparator	Aug 2018 → Jul 2019	—	Joseph Dib	Completed	No outcome recorded
Phase 4	NCT03110900 Comparator	Sep 2017 → Apr 2018	—	University of Arkansas	Terminated	No outcome recorded
Phase 4	NCT03246620 Comparator	Sep 2017 → Jun 2018	—	The University of Hong Kong	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT03075657 Comparator	May 2017 → Jun 2018	schizophrenia	All India Institute of Medical Sciences, Bhubaneswar	Completed	No outcome recorded
Phase 4	NCT02009306 Background	Jan 2017 → Feb 2018	—	Gloucestershire Hospitals NHS Foundation Trust	Completed	No outcome recorded
Phase 4	NCT02747511 Comparator	Oct 2015 → Oct 2017	migraine disorder	Western Michigan University School of Medicine	Completed	No outcome recorded
Phase 4	NCT02493192 Comparator	Jul → Dec 2015	—	Hospital General Universitario Gregorio Marañon	Unknown	No outcome recorded
Phase 4	NCT02343575 Background	Jan 2015 → Jan 2018	delirium	Stanford University	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT02380118 Comparator	Dec 2014 → Sep 2019	—	The University of Hong Kong	Terminated	No outcome recorded
Phase 4	NCT02433041 Comparator	Jul 2013 → Dec 2018	delirium	University Hospital, Basel, Switzerland	Completed	No outcome recorded
Phase 4	NCT02098499 Comparator	Jun 2013 → Feb 2015	migraine disorder	United States Naval Medical Center, Portsmouth	Withdrawn	No outcome recorded Stop: Enrollment
Phase 4	NCT02199743 Comparator	Feb 2013 → Jun 2016	schizoaffective disorder, schizophrenia	University of Texas Southwestern Medical Center	Completed	No outcome recorded
Phase 4	NCT01530308 Comparator	Nov 2012 → Apr 2015	delirium	Amsterdam UMC, location VUmc	Completed	No outcome recorded
Phase 4	NCT01193166 Comparator	Aug 2010 → Sep 2012	schizophrenia	Ortho-McNeil Janssen Scientific Affairs, LLC	Withdrawn	No outcome recorded Stop: Business
Phase 4	NCT01161277 Comparator	Aug 2010 → Jun 2011	schizophrenia	Oslo University Hospital	Completed	No outcome recorded
Phase 4	NCT01157351 Comparator	May 2010 → Dec 2013	schizophrenia	Janssen Scientific Affairs, LLC	Completed	Met primary
Phase 4	NCT01164059 Comparator	Feb 2010 → Aug 2013	schizophrenia	University of Bremen	Completed	Mixed
Phase 4	NCT00786318 Comparator	Sep 2008 → Jul 2011	delirium, psychotic disorder	George Washington University	Withdrawn	No outcome recorded
Phase 4	NCT02143531 Comparator	Sep 2008 → Aug 2012	—	American University of Beirut Medical Center	Completed	No outcome recorded
Phase 4	NCT00838032 Comparator	Aug 2008 → May 2010	schizophrenia	Sichuan University	Unknown	No outcome recorded
Phase 4	NCT00859872 Comparator	Aug 2008 → Mar 2009	schizophrenia	Central South University	Completed	No outcome recorded
Phase 4	NCT00457366 Comparator	May 2006 → Aug 2008	—	University of Southern California	Completed	No outcome recorded
Phase 4	NCT00767715 Comparator	Oct 2004 → Apr 2005	bipolar disorder	Eli Lilly and Company	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT00419653 Comparator	Jan 2003 → Sep 2007	schizophrenia	University of Jena	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT00009217 Comparator	Jan 1999 → Dec 2004	Alzheimer disease, psychotic disorder	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 4	NCT00007774 Comparator	Mar 1998 → Jun 2001	schizoaffective disorder, schizophrenia	US Department of Veterans Affairs	Completed	No outcome recorded
Phase 4	NCT00253110 Comparator	May 1996 → Sep 1998	schizoaffective disorder, schizophrenia	Janssen, LP	Completed	No outcome recorded
Phase 4	NCT00169091 Comparator	Mar 1996 → Sep 2003	schizophrenia	Harvard Medical School (HMS and HSDM)	Terminated	No outcome recorded
—	NCT06993194 Comparator	Jun 2025 → Jun 2026 overdue	delirium, traumatic brain injury	Benha University	Not yet recruiting	No outcome recorded
—	NCT06014606 Comparator	Mar 2021 → Apr 2023	—	Maastricht University	Completed	No outcome recorded
—	NCT02625181 Background	Jul 2016 → Nov 2017	—	Vanderbilt University	Completed	No outcome recorded
—	NCT01639599 Comparator	Mar → Dec 2012	female reproductive system disorder	The Catholic University of Korea	Completed	No outcome recorded
—	NCT01539733 Comparator	Mar 2010 → Apr 2017	cancer of unknown primary site, delirium	Amsterdam UMC, location VUmc	Completed	Missed primary
—	NCT01485692 Comparator	Feb 2009 → Mar 2011	—	University of Sao Paulo	Completed	No outcome recorded
—	NCT00753051 Comparator	Jun 2008 → Mar 2012	schizophrenia	Khon Kaen University	Completed	No outcome recorded
—	NCT00833300 Comparator	Jun 2008 → Nov 2011	delirium	Richard Hall	Terminated	No outcome recorded
—	NCT00642369 Comparator	Mar 2008 → Jul 2009	schizophrenia	Guang Dong Provincial Mental Health Institute	Completed	No outcome recorded
—	NCT00631722 Comparator	May 2007 → Jan 2008	schizophrenia	Peking University	Completed	No outcome recorded
—	NCT00534183 Comparator	Jun → Dec 2006	diabetes mellitus, metabolic syndrome X, obesity disorder	Central Institute of Psychiatry, Ranchi, India	Completed	No outcome recorded
—	NCT00625170 Comparator	May → Dec 2004	hyperlipidemia	Leiden University Medical Center	Completed	No outcome recorded
—	NCT00615797 Comparator	May 2002 → Dec 2009	Sydenham chorea, post-bacterial disorder	University of Cape Town	Completed	No outcome recorded
—	NCT01123408 Comparator	Jun 1999 → Jul 2004	schizophrenia	Nathan Kline Institute for Psychiatric Research	Completed	Met primary

News releases announcing trial results or a regulatory action · 4

Date	Issuer	Release
2026-06-01	Alembic Pharmaceuticals Ltd.	Regulatory 5th June, 2026 Vadodara, India alembicpharmaceuticals.com ↗ Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Haloperidol Tablets, USP, 1 mg, 2 mg, 5 mg, 10 mg, and 20 mg.
2019-10-24	Zydus Lifesciences Limited	Regulatory Liva Pharmaceuticals receives approval from the USFDA for Haloperidol Decanoate Injection zyduslife.com ↗ Liva Pharmaceuticals receives approval from the USFDA for Haloperidol Decanoate Injection
2005-12-20	Eli Lilly and Company	Results New Study Showed No Difference in Total Treatment Costs When Comparing Those Starting Treatment with Older Conventional Antipsychotics and Those Starting Treatment with Zyprexa(R), an Atypical Antipsychotic, in the Treatment of Schizophrenia lilly.com ↗ Findings indicate that any savings on medication costs were offset by the increased costs of other services associated with treatment with conventional antipsychotics including hospitalizations, crisis interventions and emergency room visits.
2005-04-06	Eli Lilly and Company	Results Studies Show Schizophrenia Patients Taking Atypicals Stayed on Treatment Longer Than Patients Taking Older, Typical Antipsychotics lilly.com ↗ Clozapine, olanzapine, and risperidone had longer time to discontinuation versus haloperidol combined with prophylactic anticholinergic agents.

All press releases naming this drug 6 releases

Date	Issuer	Release
2026-06-01	Alembic Pharmaceuticals Ltd.	5th June, 2026 Vadodara, India alembicpharmaceuticals.com ↗
2022-11-07	Upsher-Smith Laboratories	Upsher-Smith Expands Haloperidol Product Family to Include Unit Dose Tablets upsher-smith.com ↗
2020-01-13	Upsher-Smith Laboratories	Upsher-Smith Launches Haloperidol Tablets, USP upsher-smith.com ↗
2019-10-24	Zydus Lifesciences Limited	Liva Pharmaceuticals receives approval from the USFDA for Haloperidol Decanoate Injection zyduslife.com ↗
2005-12-20	Eli Lilly and Company	New Study Showed No Difference in Total Treatment Costs When Comparing Those Starting Treatment with Older Conventional Antipsychotics and Those Starting Treatment with Zyprexa(R), an Atypical Antipsychotic, in the Treatment of Schizophrenia lilly.com ↗
2005-04-06	Eli Lilly and Company	Studies Show Schizophrenia Patients Taking Atypicals Stayed on Treatment Longer Than Patients Taking Older, Typical Antipsychotics lilly.com ↗

Evidence & citations 29 cited values

Every value below carries the sentence it was read from. 139 sources stand behind the page.

Field	Value	Cited text
Known as	haloperidol	“Regular antipsychotic medications (Risperidone, Olanzapine, Clozapine, Amisulpride, Quetiapine, Paliperidone, Aripiprazole, Haloperidol, Levomepromazine, Zuclopenthixol...” NCT01323205 ↗ 132 “Drugs: Aripiprazole, Olanzapine, Zuclopenthixol, Clotiapine, Flupentixol, Risperidone, Sulpiride, Trifluoperazine, Haloperidol, Quetiapine, Paliperidone, Chlorpromazine,...” NCT01765829 ↗ “In case of early signs of a relapse prodrome based early intervention with an antipsychotic drug (Haloperidol, Risperidone and other) vs. benzodiazepine (Lorazepam) was applied...” NCT00159133 ↗ “Patients randomized to oral comparator arm will receive oral antipsychotics (haloperidol, paliperidone ER, risperidone, olanzapine, quetiapine or aripiprazole) as per...” NCT01081769 ↗ “The investigators aim to study the effectiveness of Haloperidol compared with Olanzapine in the management of hyperactive delirium in advanced cancer or end-stage organ disease...” NCT04833023 ↗ “A Randomized Double-blind, Parallel Group Study Comparing Olanzapine (Zyprexa) With Haloperidol (Novo-peridol) for the Relief of Nausea and Vomiting in Patients With Advanced Cancer” NCT00124930 ↗ “Patients received blindly olanzapine (5-20 mg/day; N=105), haloperidol (2.5-10 mg/day; N=20), or placebo (N=99) for 3 weeks.” PMID 22134043 ↗ Nov 2011 “Haloperidol (6\~20mg/day) and perphenazine (16\~64mg/day), twice per day, 8 weeks” NCT02192723 ↗ “ * Levomepromazine * Haloperidol Anti-emetic for nausea” NCT02009306 ↗ “-4mg dexamethasone, 1mg haloperidol, scopolamine patch” NCT04081545 ↗ “Haloperidol 2,5-10 mg; chlorpromazine 25-600 mg.” NCT01016145 ↗ Show 122 more sources
Known as	18F-haloperidol	“Intravenous 18F haloperidol(10 mCi)” NCT01193621 ↗
Known as	[19F]-HALOPERIDOL	ChEMBL registry synonym — accepted as the source's own label CHEMBL54 ↗
Known as	Dolpin	ChEMBL registry synonym — accepted as the source's own label CHEMBL54 ↗
Known as	Dozic	ChEMBL registry synonym — accepted as the source's own label CHEMBL54 ↗
Known as	Fortunan	ChEMBL registry synonym — accepted as the source's own label CHEMBL54 ↗
Known as	HAL	“The role of dopamine (DA) was assessed by pre-treating participants with the D2 receptor (D2R)-preferring antagonist, haloperidol (HAL; 3-mg) or mixed D1R-D2R antagonist,...” PMID 36919514 ↗ Mar 2023
Known as	Haldol	“The purpose of this study is to compare the efficacy and safety of Haldol (haloperidol) and olanzapine in the control of chronic nausea with advanced cancer patients who have...” NCT00124930 ↗ 3 “Haldol 5mg/ Ativan 2mg IM” NCT00786318 ↗ NCT03489551 ↗ NCT00493233 ↗
Known as	Haldol solutab	ChEMBL registry synonym — accepted as the source's own label CHEMBL54 ↗
Known as	Haloperidol component of vesalium	ChEMBL registry synonym — accepted as the source's own label CHEMBL54 ↗
Known as	Haloperidol decanoate impurity, haloperidol-	ChEMBL registry synonym — accepted as the source's own label CHEMBL54 ↗
Known as	HALOPERIDOL HYDROCHLORIDE	ChEMBL registry synonym — accepted as the source's own label CHEMBL54 ↗
Known as	Haloperidol Injection	“Drug: Haloperidol Injection” NCT06168773 ↗
Known as	Haloperidol Tables, H31021234	“Haloperidol Tables, H31021234” NCT04071639 ↗
Known as	haloperidole	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01157351 ↗ 1 NCT00433121 ↗
Known as	Kentace	ChEMBL registry synonym — accepted as the source's own label CHEMBL54 ↗
Known as	Keselen	ChEMBL registry synonym — accepted as the source's own label CHEMBL54 ↗
Known as	MCN-JR-1625	ChEMBL registry synonym — accepted as the source's own label CHEMBL54 ↗
Known as	Novo-peridol	“A Randomized Double-blind, Parallel Group Study Comparing Olanzapine (Zyprexa) With Haloperidol (Novo-peridol) for the Relief of Nausea and Vomiting in Patients With Advanced Cancer” NCT00124930 ↗
Known as	NSC-170973	ChEMBL registry synonym — accepted as the source's own label CHEMBL54 ↗
Known as	NSC-615296	ChEMBL registry synonym — accepted as the source's own label CHEMBL54 ↗
Known as	R-1625	ChEMBL registry synonym — accepted as the source's own label CHEMBL54 ↗
Known as	Serenace	ChEMBL registry synonym — accepted as the source's own label CHEMBL54 ↗
Known as	TEVA-HALOPERIDOL	“The oral investigational agent haloperidol (Generic Brand: TEVA-HALOPERIDOL) will be self-administered, at night, over 7 days.” NCT07109245 ↗
Action	Inhibit	“Typical antipsychotics, like haloperidol, are dopamine antagonists” NCT01161277 ↗ 1 “Serotonin 2a (5-HT2a) receptor antagonist” CHEMBL54 ↗
Modality	Other / unclassified	“haloperidol, a typical anti- psychotic” NCT04176055 ↗
Route	Oral	“receive 20 weeks of open haloperidol treatment with an oral dose of 1-5 mg daily” NCT00009217 ↗
Target	DRD2	“DRD2 antagonist haloperidol” NCT06218524 ↗
Target	HTR2A	“Serotonin 2a (5-HT2a) receptor antagonist” CHEMBL54 ↗